Recently, Sanyuan Gene, a company listed on the Beijing Stock Exchange, stated in discussions with investors that it will adhere to the principle of "prudent research and steady advancement." The company aims to explore pathways for external investment and mergers centered around its main business direction. It plans to fully utilize various tools and platforms within the capital market to seek high-quality investment or merger targets that can synergistically develop across research, production, and sales, with the goal of achieving higher quality development in both serious medicine and therapeutic medicine markets.

In the pharmaceutical sector, the development of innovative drug companies is a critical component of new productive forces and is receiving significant attention from capital markets. As a national-level specialized "little giant" enterprise, Sanyuan Gene has been deeply involved in the biopharmaceutical field for 32 years. Since its listing on the Beijing Stock Exchange, the company has actively responded to national policy initiatives and is accelerating its development pace, guided by new productive forces. The company’s board of directors noted in the previously released "2023 Social Responsibility Report" that Sanyuan Gene is currently experiencing one of the most dynamic growth periods in its 30-year history.

Currently, the company has four key new drug research and development projects advancing steadily, with the commercialization of potential new drugs forthcoming. According to Sanyuan Gene's "2024 Semi-Annual Report," the company's clinical trial project for inhalation treatment with recombinant human interferon α1b for pediatric respiratory syncytial virus (RSV) pneumonia is progressing well. The company has completed the preparation of registration materials for clinical trial statistics and inhalation quality research in accordance with registration review requirements and has communicated with the Center for Drug Evaluation of the National Medical Products Administration, planning to formally submit a listing application.

Additionally, Sanyuan Gene's new intelligent production and research base has been completed. The company aims to continuously enhance product quality and management levels based on the new facility, and to strive to set up a benchmark enterprise in the biopharmaceutical sector following the principles of "Industry 4.0."

Looking ahead, Sanyuan Gene stated it will leverage favorable policies to enhance its core competitiveness and continue progressing towards high-quality development.

https://finance.eastmoney.com/a/202409273193401756.html